{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T06:58:41Z","timestamp":1785481121798,"version":"3.56.0"},"reference-count":31,"publisher":"American Chemical Society (ACS)","issue":"18","license":[{"start":{"date-parts":[[2025,9,16]],"date-time":"2025-09-16T00:00:00Z","timestamp":1757980800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,9,16]],"date-time":"2025-09-16T00:00:00Z","timestamp":1757980800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,9,16]],"date-time":"2025-09-16T00:00:00Z","timestamp":1757980800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-045"}],"funder":[{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["R01CA266057"],"award-info":[{"award-number":["R01CA266057"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,9,25]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Mixed lineage leukemia (MLL) gene rearrangements cause \u223c75% of acute leukemia in infants and 5\u201310% in children and adults with poor clinical outcomes. Protein\u2013protein interactions (PPI) between frequent MLL fusion partners AF9\/ENL and AF4 or histone methyltransferase DOT1L are drug targets for MLL-rearranged (MLL-r) leukemia. Sixty-seven quinoxiline compounds were synthesized and tested for their ability to inhibit such PPIs. Compounds 16, 17, 59, and 63 were found to be potent inhibitors with IC50 values of 0.35\u20131.5 \u03bcM. Structure\u2013activity relationships are discussed. Potent inhibitors can suppress the expression of MLL target genes Myc and Meis1 and selectively block the proliferation of MLL-r and several other leukemia cells with EC50 values as low as 0.84 \u03bcM. Compound 17 exhibited significant antitumor activities in a mouse model of MLL-r leukemia without overt toxicities. It also showed favorable pharmacokinetics in mice. These results indicate that compound 17 is a promising pharmaceutical lead for the treatment of MLL-r leukemia.<\/jats:p>","DOI":"10.1021\/acs.jmedchem.5c01587","type":"journal-article","created":{"date-parts":[[2025,9,16]],"date-time":"2025-09-16T21:47:56Z","timestamp":1758059276000},"page":"19396-19414","source":"Crossref","is-referenced-by-count":4,"title":["Synthesis,\nStructure\u2013Activity Relationships,\nand Antitumor Activities of Quinoxiline-Containing Inhibitors of the\nProtein\u2013Protein Interactions between Transcription Coactivator\nAF9\/ENL and DOT1L\/AF4"],"prefix":"10.1021","volume":"68","author":[{"given":"Chandra Bhushan","family":"Mishra","sequence":"first","affiliation":[{"name":"Baylor College of Medicine , , 1 Baylor Plaza , , ,","place":["Houston, Texas, United States, 77030"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0189-4371","authenticated-orcid":true,"given":"Xin","family":"Li","sequence":"additional","affiliation":[{"name":"Baylor College of Medicine , , 1 Baylor Plaza , , ,","place":["Houston, Texas, United States, 77030"]},{"name":"Baylor College of Medicine , , 1 Baylor Plaza , , ,","place":["Houston, Texas, United States, 77030"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bala Krishna","family":"Moku","sequence":"additional","affiliation":[{"name":"Baylor College of Medicine , , 1 Baylor Plaza , , ,","place":["Houston, Texas, United States, 77030"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sehun","family":"Kwak","sequence":"additional","affiliation":[{"name":"Baylor College of Medicine , , 1 Baylor Plaza , , ,","place":["Houston, Texas, United States, 77030"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dnyaneshwar N.","family":"Garad","sequence":"additional","affiliation":[{"name":"Baylor College of Medicine , , 1 Baylor Plaza , , ,","place":["Houston, Texas, United States, 77030"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2611-2476","authenticated-orcid":true,"given":"Yongcheng","family":"Song","sequence":"additional","affiliation":[{"name":"Baylor College of Medicine , , 1 Baylor Plaza , , ,","place":["Houston, Texas, United States, 77030"]},{"name":"Baylor College of Medicine , , 1 Baylor Plaza , , ,","place":["Houston, Texas, United States, 77030"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"316","published-online":{"date-parts":[[2025,9,16]]},"reference":[{"issue":"11","key":"2026073102135544400_cit1","doi-asserted-by":"publisher","first-page":"823","DOI":"10.1038\/nrc2253","article-title":"MLL translocations, histone modifications and leukaemia\nstem-cell development","volume":"7","author":"Krivtsov","year":"2007","journal-title":"Nat. Rev. Cancer"},{"issue":"3","key":"2026073102135544400_cit2","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1016\/j.semcancer.2005.01.007","article-title":"The versatile mixed\nlineage leukaemia gene MLL and\nits many associations in leukaemogenesis","volume":"15","author":"Daser","year":"2005","journal-title":"Semin.\nCancer Biol."},{"issue":"24","key":"2026073102135544400_cit3","doi-asserted-by":"publisher","first-page":"6061","DOI":"10.1182\/blood-2008-12-197061","article-title":"Therapeutic targeting\nof MLL","volume":"113","author":"Liedtke","year":"2009","journal-title":"Blood"},{"issue":"9","key":"2026073102135544400_cit4","doi-asserted-by":"publisher","first-page":"2386","DOI":"10.1182\/blood.V81.9.2386.2386","article-title":"Molecular rearrangements\non chromosome 11q23 predominate in infant acute lymphoblastic leukemia\nand are associated with specific biologic variables and poor outcome","volume":"81","author":"Chen","year":"1993","journal-title":"Blood"},{"issue":"11","key":"2026073102135544400_cit5","doi-asserted-by":"publisher","first-page":"3250","DOI":"10.1182\/blood.V85.11.3250.bloodjournal85113250","article-title":"ALL-1 gene rearrangements in DNA\ntopoisomerase II inhibitor-related leukemia in children","volume":"85","author":"Felix","year":"1995","journal-title":"Blood"},{"issue":"11","key":"2026073102135544400_cit6","doi-asserted-by":"publisher","first-page":"4532","DOI":"10.1182\/blood.V90.11.4532","article-title":"Adult\npatients with\nde novo acute myeloid leukemia and t(9; 11)(p22; q23) have a superior\noutcome to patients with other translocations involving band 11q23:\na cancer and leukemia group B study","volume":"90","author":"Mrozek","year":"1997","journal-title":"Blood"},{"issue":"12","key":"2026073102135544400_cit7","doi-asserted-by":"publisher","first-page":"3705","DOI":"10.1182\/blood.V82.12.3705.3705","article-title":"Rearrangements\nof the MLL gene in therapy-related acute myeloid leukemia in patients\npreviously treated with agents targeting DNA-topoisomerase II","volume":"82","author":"Super","year":"1993","journal-title":"Blood"},{"issue":"1\u20133","key":"2026073102135544400_cit8","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1016\/S0167-4781(98)00139-0","article-title":"Secondary\nleukemias induced by topoisomerase-targeted drugs","volume":"1400","author":"Felix","year":"1998","journal-title":"Biochim. Biophys. Acta, Gene Struct. Expression"},{"issue":"2","key":"2026073102135544400_cit9","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1038\/leu.2017.213","article-title":"The MLL recombinome of acute leukemias\nin 2017","volume":"32","author":"Meyer","year":"2018","journal-title":"Leukemia"},{"issue":"1","key":"2026073102135544400_cit10","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-021-01057-7","article-title":"Structure, function\nand inhibition of critical protein\u2013protein\ninteractions involving mixed lineage leukemia 1 and its fusion oncoproteins","volume":"14","author":"Li","year":"2021","journal-title":"J. Hematol. Oncol."},{"issue":"2","key":"2026073102135544400_cit11","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1016\/j.ccr.2009.12.040","article-title":"A higher-order complex\ncontaining AF4 and ENL family proteins with P-TEFb facilitates oncogenic\nand physiologic MLL-dependent transcription","volume":"17","author":"Yokoyama","year":"2010","journal-title":"Cancer Cell"},{"issue":"6","key":"2026073102135544400_cit12","doi-asserted-by":"publisher","first-page":"574","DOI":"10.1101\/gad.1898410","article-title":"Linking H3K79\ntrimethylation to Wnt signaling through a novel Dot1-containing complex\n(DotCom)","volume":"24","author":"Mohan","year":"2010","journal-title":"Genes Dev."},{"issue":"3","key":"2026073102135544400_cit13","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1016\/j.molcel.2010.01.026","article-title":"AFF4, a component\nof the ELL\/P-TEFb elongation complex\nand a shared subunit of MLL chimeras, can link transcription elongation\nto leukemia","volume":"37","author":"Lin","year":"2010","journal-title":"Mol. Cell"},{"issue":"17","key":"2026073102135544400_cit14","doi-asserted-by":"publisher","first-page":"8172","DOI":"10.7150\/thno.56737","article-title":"Small-molecule inhibitor\nof AF9\/ENL-DOT1L\/AF4\/AFF4 interactions suppresses\nmalignant gene expression and tumor growth","volume":"11","author":"Wu","year":"2021","journal-title":"Theranostics"},{"issue":"21","key":"2026073102135544400_cit15","doi-asserted-by":"publisher","first-page":"5283","DOI":"10.3390\/cancers15215283","article-title":"Discovery,\nStructure-Activity Relationship and In Vitro Anticancer Activity of\nSmall-Molecule Inhibitors of the Protein-Protein Interactions between\nAF9\/ENL and AF4 or DOT1L","volume":"15","author":"Li","year":"2023","journal-title":"Cancers"},{"issue":"5","key":"2026073102135544400_cit16","doi-asserted-by":"publisher","first-page":"808","DOI":"10.1016\/j.celrep.2015.04.004","article-title":"Degree of recruitment of DOT1L to\nMLL-AF9 defines level\nof H3K79 Di- and tri-methylation on target genes and transformation\npotential","volume":"11","author":"Kuntimaddi","year":"2015","journal-title":"Cell Rep."},{"issue":"1","key":"2026073102135544400_cit17","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1016\/j.str.2012.11.011","article-title":"Leukemia\nfusion target AF9 is an\nintrinsically disordered transcriptional regulator that recruits multiple\npartners via coupled folding and binding","volume":"21","author":"Leach","year":"2013","journal-title":"Structure"},{"issue":"5","key":"2026073102135544400_cit18","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1016\/j.ccr.2008.10.001","article-title":"H3K79 methylation profiles define murine and\nhuman MLL-AF4 leukemias","volume":"14","author":"Krivtsov","year":"2008","journal-title":"Cancer Cell"},{"issue":"22","key":"2026073102135544400_cit19","doi-asserted-by":"publisher","first-page":"8972","DOI":"10.1021\/jm4007752","article-title":"A medicinal chemistry perspective for targeting histone H3 lysine-79\nmethyltransferase DOT1L","volume":"56","author":"Anglin","year":"2013","journal-title":"J. Med. Chem."},{"issue":"1","key":"2026073102135544400_cit20","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-022-01251-1","article-title":"Targeting the histone\nH3 lysine 79 methyltransferase DOT1L in MLL-rearranged\nleukemias","volume":"15","author":"Yi","year":"2022","journal-title":"J. Hematol. Oncol."},{"issue":"6","key":"2026073102135544400_cit21","doi-asserted-by":"publisher","first-page":"1017","DOI":"10.1182\/blood-2013-04-497644","article-title":"Potent inhibition of\nDOT1L as treatment of MLL-fusion leukemia","volume":"122","author":"Daigle","year":"2013","journal-title":"Blood"},{"issue":"9","key":"2026073102135544400_cit22","doi-asserted-by":"publisher","first-page":"895","DOI":"10.1021\/acsmedchemlett.8b00175","article-title":"Peptidomimetics\nfor Targeting Protein-Protein\nInteractions between DOT1L and MLL Oncofusion Proteins AF9 and ENL","volume":"9","author":"Du","year":"2018","journal-title":"ACS Med. Chem. Lett."},{"issue":"11","key":"2026073102135544400_cit23","doi-asserted-by":"publisher","first-page":"7770","DOI":"10.1021\/acs.jmedchem.2c00083","article-title":"Design, Synthesis,\nand Biological Evaluations of DOT1L Peptide Mimetics Targeting the\nProtein-Protein Interactions between DOT1L and MLL-AF9\/MLL-ENL","volume":"65","author":"Yuan","year":"2022","journal-title":"J. Med. Chem."},{"issue":"1","key":"2026073102135544400_cit24","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-022-01258-8","article-title":"A proteolysis-targeting chimera molecule\nselectively degrades ENL and inhibits malignant gene expression and\ntumor growth","volume":"15","author":"Li","year":"2022","journal-title":"J. Hematol. Oncol."},{"issue":"7644","key":"2026073102135544400_cit25","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1038\/nature21688","article-title":"Transcription control\nby the ENL YEATS domain\nin acute leukaemia","volume":"543","author":"Erb","year":"2017","journal-title":"Nature"},{"issue":"7644","key":"2026073102135544400_cit26","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1038\/nature21687","article-title":"ENL links histone acetylation to oncogenic\ngene expression in acute\nmyeloid leukaemia","volume":"543","author":"Wan","year":"2017","journal-title":"Nature"},{"issue":"42","key":"2026073102135544400_cit27","doi-asserted-by":"publisher","first-page":"16746","DOI":"10.1021\/ja206312b","article-title":"Selective inhibitors\nof histone methyltransferase DOT1L: design, synthesis, and crystallographic\nstudies","volume":"133","author":"Yao","year":"2011","journal-title":"J. Am. Chem. Soc."},{"issue":"18","key":"2026073102135544400_cit28","doi-asserted-by":"publisher","first-page":"8066","DOI":"10.1021\/jm300917h","article-title":"Synthesis and structure\u2013activity\nrelationship investigation\nof adenosine-containing inhibitors of histone methyltransferase DOT1L","volume":"55","author":"Anglin","year":"2012","journal-title":"J. Med. Chem."},{"issue":"5","key":"2026073102135544400_cit29","doi-asserted-by":"publisher","first-page":"910","DOI":"10.1038\/leu.2011.315","article-title":"Synergistic\ninduction of p53 mediated\napoptosis by valproic acid and nutlin-3 in acute myeloid leukemia","volume":"26","author":"McCormack","year":"2012","journal-title":"Leukemia"},{"issue":"7","key":"2026073102135544400_cit30","doi-asserted-by":"publisher","first-page":"1478","DOI":"10.1182\/bloodadvances.2019000986","article-title":"Quizartinib-resistant\nFLT3-ITD acute myeloid leukemia cells are sensitive to the FLT3-Aurora\nkinase inhibitor CCT241736","volume":"4","author":"Moore","year":"2020","journal-title":"Blood Adv."},{"issue":"3","key":"2026073102135544400_cit31","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1016\/j.cmpb.2010.01.007","article-title":"PKSolver: An add-in program for pharmacokinetic\nand pharmacodynamic data analysis in Microsoft Excel","volume":"99","author":"Zhang","year":"2010","journal-title":"Comput. Methods Programs Biomed."}],"container-title":["Journal of Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/pubs.acs.org\/doi\/pdf\/10.1021\/acs.jmedchem.5c01587","content-type":"application\/pdf","content-version":"vor","intended-application":"unspecified"},{"URL":"https:\/\/pubs.acs.org\/jmcmar\/article-pdf\/68\/18\/19396\/66295332\/acs.jmedchem.5c01587.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/pubs.acs.org\/jmcmar\/article-pdf\/68\/18\/19396\/66295332\/acs.jmedchem.5c01587.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T06:14:01Z","timestamp":1785478441000},"score":1,"resource":{"primary":{"URL":"https:\/\/pubs.acs.org\/jmcmar\/article\/68\/18\/19396\/5234807\/Synthesis-Structure-Activity-Relationships-and"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,16]]},"references-count":31,"journal-issue":{"issue":"18","published-online":{"date-parts":[[2025,9,16]]},"published-print":{"date-parts":[[2025,9,25]]}},"URL":"https:\/\/doi.org\/10.1021\/acs.jmedchem.5c01587","relation":{},"ISSN":["0022-2623","1520-4804"],"issn-type":[{"value":"0022-2623","type":"print"},{"value":"1520-4804","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,16]]}}}